Periodic Reporting for period 4 - IMMUNEDIVERSITY (Defining of human adaptive immune gene diversity and its impact on disease)
Período documentado: 2023-06-01 hasta 2024-11-30
This ERC Advanced project focuses on the genes that encode our adaptive immune receptors, that is our B- and T-cell receptors (BCRs and TCRs). Surprisingly, this area of immunogenetics remains understudied as these genomic regions are not covered by conventional whole genome sequencing approaches. A central goal of this project has been to develop and use specialized sequencing and analysis tools that allow definition of genetic variability in these genes and to apply them to large population groups. In doing so, we can characterize the genetic diversity in BCR and TCR germline genes, both in the form of allelic and copy number variation, resulting in the generation of an improved databases of V, D, and J alleles.
Why is it important for society?
An improved understanding of the genes that encode our TCRs and BCRs is medically highly relevant as adaptive immune responses are central in health and disease. The adaptive immune system is well-known for providing immunological memory, which is the basis for vaccine-induced protection and control of re-infections. However, adaptive immune responses are also involved in numerous other common diseases, including allergy and autoimmune conditions, such as rheumatoid arthritis, multiple sclerosis and diabetes. An improved knowledge about human genetic variability in germline-encoded BCR and TCR V, D, and J genes helps us understand human responses to specific pathogens and provides important information for investigations aimed at understanding the development of immune-mediated diseases. Furthermore, by studying these highly diverse genomic loci, we obtain information that guide studies of human migration and evolution to better understand how we have adapted to external pressures during our history.
What are the overall objectives?
Over the course of this grant period, our work has resulted in the creation of adaptive immune receptor gene databases from thousands of individuals, which we will make publicly accessible upon publication of the studies. We have also developed robust library production protocols for immune receptor (expressed and genomic) sequencing that other immunology laboratory can replicate and we will continue to produce freely accessible software tools that can be installed and used by competent researchers. Furthermore, during this grant period, we have begun to apply these methods to human disease cohorts to investigate if certain adaptive immune receptor gene variants are risk factors for autoimmune diseases.
The most significant achievement in the ImmuneDiversity project has been to establish a highly precise, high throughput technique for typing human adaptive immune receptor genes, that is all BCR and TCR V, D and J genes. The ImmuneDiscover technique is based on a targeted multiple locus sequencing approach and computational analysis pipelines that ensure the specificity of the technique. The technique requires minimal amounts of genomic DNA and thus enables immune profiling from sources such as archived biobank DNA. This is a scientific breakthrough as it means that we can process not just hundreds, but thousands of samples in just a few months, which was technically unfeasible previously. During this ERC project, we applied ImmuneDiscover to over 2500 cases from the 1000 Genomes Project (1KGP) sample collection and other cohorts, comprising 5 super-populations (African, European, East Asian, South Asian and American), representing 25 sub-population groups. We have just completed the analyses of the BCR loci and identified over 500 novel IGHV alleles. We also determined the frequency of each allele in the 25 different groups, resulting in an atlas of gene variant present in the different populations, which we are reporting for the first time in an upcoming publication and a user-friendly website (Corcoran et al. manuscript in submission). This is a major undertaking, which we are currently extending to the TCR loci. Finally, we have used the ImmuneDiscover technique to sequence a large cohort of indviduals with rheumatoid arthritis and controls, generating an extensive data set that is now being analyzed.
We have presented our progress in several international conferences and workshops and we have initiated valuable pre-clinical and clinical collaborations where we utilize the ImmuneDiscover technique to study questions related to human evolution and autoimmune diseases.
 
           
        